AlanMarvinKellerMD

PubMed

• 364 citations
  Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer
  Giorgio V. Scagliotti, Silvia Novello, Joachim von Pawel, Martin Reck, José Rodrigues Pereira, Michael Thomas, Jose Elias Abrao Miziara, Beatrix Bálint, Filippo de Mar...> ;Journal of Clinical Oncology. 2010 Apr 10
• The influence of bisphosphonates on bone turnover markers in patients (pts) with breast cancer (BC).
  Keller A, Heim K, Welzel G, Findeisen P, Neumaier M, Wenz F> ;J. Clin. Oncol.. 2009-05-20
• 58 citations
  Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer
  Anthony L.A. Fields, Alan Keller, Lee S. Schwartzberg, Stephen A. Bernard, Carl Kardinal, Alan R. Cohen, Joe Schulz, Peter D. Eisenberg, John K. Forster, Paul Wissel> ;Journal of Clinical Oncology. 2009 Apr 20
• Bone remodeling markers in breast and prostate cancer patients undergoing endocrine and bisphosponate therapy.
  Wenz FK, Welzel G, Keller A, Findeisen P, Neumaier M, Hermann B> ;J. Clin. Oncol.. 2008-05-20
• The influence of the interval between IORT during breast-conserving surgery and external beam radiotherapy (EBRT) on late toxicity.
  Welzel G, Blank E, Kraus-Tiefenbacher U, Keller A, Vorodi F, Herskind C, Tome O, Sütterlin M, Wenz FK> ;J. Clin. Oncol.. 2008-05-20
• 164 citations
  Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer
  Alan M. Keller, Robert G. Mennel, Vassilis A. Georgoulias, Jean Marc Nabholtz, Aura Erazo, Anna Lluch, Charles L. Vogel, Manfred Kaufmann, Gunther von Minckwitz, I. Cr...> ;Journal of Clinical Oncology. 2004 Oct 1
• A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by either weekly paclitaxel or observation in patients with stage III ...
  Carter DL, Keller AM, Tolley RC, Johnson DB, Hathorn J, Mundis RJ, O'Rourke MA, Ilegbodu D, Asmar L> ;J. Clin. Oncol.. 2004-07-15
• 182 citations
  Further Evaluation of Intensified and Increased Total Dose of Cyclophosphamide for the Treatment of Primary Breast Cancer: Findings From National Surgical Adjuvant Bre...
  Bernard Fisher, Stewart J. Anderson, Arthur DeCillis, Nikolay V. Dimitrov, James N. Atkins, Louis Fehrenbacher, Patrick H. Henry, Edward H. Romond, Keith S. Lanier, En...> ;Journal of Clinical Oncology. 1999 Nov 1
• 476 citations
  Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
  James R. Berenson, Alan Lichtenstein, Lester Porter, Meletios A. Dimopoulos, Roldolfo Bordoni, Sebastian George, Alan Lipton, Alan Keller, O. F. Ballester, Michael J. ...> ;Journal of Clinical Oncology. 1998 Feb 1
• 757 citations
  Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
  James R. Berenson, Alan Lichtenstein, Lester Porter, Meletios A. Dimopoulos, Roldolfo Bordoni, Sebastian George, Allan Lipton, Alan Keller, O. F. Ballester, Michael J....> ;The New England Journal of Medicine. 1996 Feb 22
• Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease.
  Miralbell R, Bieri S, Mermillod B, Helg C, Sancho G, Pastoors B, Keller A, Kurtz JM, Chapuis B> ;J. Clin. Oncol.. 1996-02-01
• Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
  Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP, Tauer K, Neidhart J, Mallette LE, Siegel R> ;J. Clin. Oncol.. 1992-01-01
• 6 citations
  Prolonged survival after high-dose cytosine arabinoside and amsacrine induction in patients with previously untreated de novo acute nonlymphocytic leukemia.
  John D. Hines, Joseph J. Mazza, Martin M. Oken, David J. Adelstein, Alan Keller, John M. Bennett, Michael J. O'Connell> ;Seminars in Oncology. 1987 Jun 1
• High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study f...
  Hines JD, Mazza JJ, Oken MM, Bennett JM, Adelstein DJ, Keller A, O'Connell MJ> ;Semin. Oncol.. 1985-06-01
• High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
  Hines JD, Oken MM, Mazza JJ, Keller AM, Streeter RR, Glick JH> ;J. Clin. Oncol.. 1984-06-01
• Join now to see all